newsfilter
← Latest News
PR Newswire·

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

  • HitGen Inc. congratulates partner BioAge Labs on dosing the first participant in the Phase 2 QUELL-CV trial for BGE-102.
  • BGE-102 is a once-daily oral NLRP3 inhibitor developed from HitGen's DEL technology platform with cardiovascular risk reduction as the lead indication.
  • Phase 1 results demonstrated profound hsCRP reductions & good tolerability, positioning BGE-102 as a potential best-in-class candidate.
  • The randomized, double-blind Phase 2 trial aims to determine optimal dosing for future Phase 3 studies in participants with elevated cardiovascular risk.
  • Topline data for the QUELL-CV trial are expected in the second half of 2026.
  • HitGen's CEO Dr. Jin Li highlighted the success of their DEL platform & collaborative model in generating novel small-molecule leads.
  • BioAge CEO Kristen Fortney noted that the molecule engages a novel NLRP3 binding site & praised the partnership for advancing drug discovery.
  • As of the end of 2025, HitGen has partnered with over 600 global clients to contribute to thousands of drug development projects.